WBWilliam E. Brady
William E. Brady
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William E. Brady has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Kathleen Nadine Moore
University of Nebraska Medical Center, Omaha, NE
4 shared publications - David M. Gershenson
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
3 shared publications - Don S. Dizon
Legorreta Cancer Center, Brown University, Providence, RI
2 shared publications - Heather A. Lankes
NRG Oncology Statistics & Data Management Center, Roswell Park Cancer Institute, Buffalo, NY 14263, United States
2 shared publications - Paula M. Fracasso
UVA Cancer Center
2 shared publications - Russell J. Schilder
Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA
2 shared publications
Latest Publications
- 1 November 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 151 (2) , 202-207
A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study
- 1 November 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 151 (2) , 202-207
A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study
- 1 July 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 150 (1) , 9-13
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
- 1 July 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 150 (1) , 9-13
Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)
- 1 June 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 149 (3) , 605-611
Clinical trial methodology in rare gynecologic tumor research: Strategies for success
- 1 June 2018
- Published by Elsevier in Gynecologic Oncology
- Vol. 149 (3) , 605-611
Clinical trial methodology in rare gynecologic tumor research: Strategies for success
- 1 November 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (2) , 243-249
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
- 1 November 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (2) , 243-249
An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience
- 1 November 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (2) , 283-290
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study
- 1 November 2017
- Published by Elsevier in Gynecologic Oncology
- Vol. 147 (2) , 283-290
A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study
- 1 February 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 140 (2) , 264-269
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study
- 1 February 2016
- Published by Elsevier in Gynecologic Oncology
- Vol. 140 (2) , 264-269
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study